These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16596244)

  • 1. Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma.
    Khan SA; Taylor-Robinson SD; Carmichael PL; Habib N; Lemoine NR; Thomas HC
    Int J Oncol; 2006 May; 28(5):1269-77. PubMed ID: 16596244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Mutations in human cholangiocarcinoma: a review.
    Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
    Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients.
    Petmitr S; Pinlaor S; Thousungnoen A; Karalak A; Migasena P
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):71-5. PubMed ID: 9740272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.
    Kang YK; Kim WH; Lee HW; Lee HK; Kim YI
    Lab Invest; 1999 Apr; 79(4):477-83. PubMed ID: 10212000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer.
    Besaratinia A; Bates SE; Pfeifer GP
    Cancer Res; 2002 Aug; 62(15):4331-8. PubMed ID: 12154037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer genes and cholangiocarcinoma.
    Petmitr S
    Southeast Asian J Trop Med Public Health; 1997; 28 Suppl 1():80-4. PubMed ID: 9656355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
    Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
    Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers.
    Tornaletti S; Pfeifer GP
    Oncogene; 1995 Apr; 10(8):1493-9. PubMed ID: 7731703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast.
    Kamikawa T; Amenomori M; Itoh T; Momoi H; Hiai H; Machinami R; Ishikawa Y; Mori T; Shimahara Y; Yamaoka Y; Fukumoto M
    Radiat Res; 1999 Dec; 152(6 Suppl):S118-24. PubMed ID: 10564951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of K-ras codon 12 mutations in cholangiocarcinoma detected by polymerase chain reaction technique.
    Wattanasirichaigoon S; Tasanakhajorn U; Jesadapatarakul S
    J Med Assoc Thai; 1998 May; 81(5):316-23. PubMed ID: 9623030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rates of Ki-ras point mutation in both intra- and extra-hepatic cholangiocarcinomas.
    Ohashi K; Tsutsumi M; Nakajima Y; Noguchi O; Okita S; Kitada H; Tsujiuchi T; Kobayashi E; Nakano H; Konishi Y
    Jpn J Clin Oncol; 1994 Dec; 24(6):305-10. PubMed ID: 7830335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
    Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
    Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of tumour-associated and germ line p53 mutations in canine mammary cancer.
    Veldhoen N; Watterson J; Brash M; Milner J
    Br J Cancer; 1999 Oct; 81(3):409-15. PubMed ID: 10507764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinogen-induced impairment of enzymes for replicative fidelity of DNA and the initiation of tumours.
    Bignold LP
    Carcinogenesis; 2004 Mar; 25(3):299-307. PubMed ID: 14604890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New p53 mutations in hilar cholangiocarcinoma.
    Tullo A; D'Erchia AM; Honda K; Kelly MD; Habib NA; Saccone C; Sbisà E
    Eur J Clin Invest; 2000 Sep; 30(9):798-803. PubMed ID: 10998080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
    Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
    Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma.
    Liu XF; Zhang H; Zhu SG; Zhou XT; Su HL; Xu Z; Li SJ
    World J Gastroenterol; 2006 Aug; 12(29):4706-9. PubMed ID: 16937443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational biases associated with potential iron-binding DNA motifs in rodent lacI and human p53 mutational databases.
    Sonntag DM; de Boer J; Medvedovic M; Baxter CS; LeMasters G; Talaska G
    Mutat Res; 2004 Jun; 550(1-2):73-88. PubMed ID: 15135642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of epigenetic alterations in cholangiocarcinoma.
    Tischoff I; Wittekind C; Tannapfel A
    J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.